Taiwan Vaccine Companies and Products
As of October 23, 2026, this table includes vaccine products or clinical programs at 3 Taiwan companies, with cancelled products and therapeutic cell vaccines explicitly identified. [1] [2] [3] [4] [5] [6]
Taiwan licenses for Adimmune trivalent and quadrivalent AdimFlu-S remain within their validity periods, while AdimFlu-V is cancelled; Medigen entries include Vietnam authorization for ENVACGEN, historical Taiwan EUA for MVC-COV1901 and a pause in variant-vaccine R&D investment disclosed in the 2025 annual report; ADCV01 is a recruiting Phase 2 therapeutic vaccine. [1] [2] [3] [4] [5] [6]
| Company | Ticker | Product / pipeline | Indication | Latest verified stage | Stage source and date | Most recent catalyst |
|---|---|---|---|---|---|---|
| Adimmune Company source | 4142 | AdimFlu-S (trivalent); AdimFlu-S (QIS) (quadrivalent); AdimFlu-V (virosomal, historical product) Product source | Prevention of influenza; current AdimFlu-S and QIS product pages specify ages 3 years and older; AdimFlu-V is a historical influenza vaccine | AdimFlu-S: license issued September 2010, valid through October 2031; QIS: issued June 2017, valid through June 2027; AdimFlu-V: issued July 2014, cancelled June 2022 because the validity period had expired | 2026-10-23 Stage source 2031/10/30 | — |
| Medigen Vaccine Biologics Company source | 6547 | ENVACGEN (enterovirus A71 vaccine); MVC-COV1901 (MVC COVID-19 Vaccine) Product source | ENVACGEN: prevention of enterovirus A71 disease; MVC-COV1901: active immunization against COVID-19 in adults aged 20 years and older | ENVACGEN: Vietnam marketing authorization in March 2026; original-strain MVC-COV1901: Taiwan conditional special manufacturing authorization in July 2021 (EUA, not regular approval); the April 2025 annual report states that COVID-19 variant-vaccine R&D investment has been paused | 2026-03-17 Stage source has received marketing authorization | — |
| Ever Supreme Bio Technology Company source | 6712 | ADCV01 (therapeutic autologous dendritic-cell vaccine) | Add-on treatment for primary glioblastoma multiforme | Phase 2; RECRUITING (NCT04115761) | 2026-09-24 Stage source RECRUITING | — |
Scope and public-document limits
This is a product selection rather than a complete census, with one row per company. License validity, historical special manufacturing authorization and seasonal supply are distinct. The MVC-COV1901 entry follows the current company page and TFDA authorization documents; EUA is not regular approval or a statement of current public-program supply.